-
公开(公告)号：US20190144825A1
公开(公告)日：2019-05-16
申请号：US16092068
申请日：2017-04-05
申请人： Emory University
发明人： Edmund Waller , Anna Morris , Christopher Petersen , Jian-Ming Li , Reema Panjwani , Jingxia Li
IPC分类号： C12N5/0783 , A61K35/28 , A61K35/17 , A61K38/22 , A61K38/54 , A61P35/00 , C07K16/28 , A61P31/00
摘要： This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.
-
公开(公告)号：US11850263B2
公开(公告)日：2023-12-26
申请号：US16763197
申请日：2018-11-09
CPC分类号： A61K35/17 , A61K47/62 , A61K47/6935 , C07K14/57563 , A61K9/0019 , A61K38/00
摘要： This disclosure relates to compositions comprising an antagonist of vasoactive intestinal polypeptide signaling coupled to a nanoparticle and methods of use related thereto. In certain embodiments, the nanoparticle is a poloxamer-stabilized polypropylene sulfide nanoparticle.
-
公开(公告)号：US20240271092A1
公开(公告)日：2024-08-15
申请号：US18510060
申请日：2023-11-15
申请人： Emory University
发明人： Edmund Waller , Anna Morris , Christopher Petersen , Jian-Ming Li , Reema Panjwani , Jingxia Li
IPC分类号： C12N5/0783 , A61K35/17 , A61K35/28 , A61K38/20 , A61K38/22 , A61K38/48 , A61K38/54 , A61K39/39 , A61K45/06 , A61P31/00 , A61P35/00 , C07K16/28
CPC分类号： C12N5/0638 , A61K35/17 , A61K35/28 , A61K38/208 , A61K38/22 , A61K38/482 , A61K38/4886 , A61K38/54 , A61K39/39 , A61K45/06 , A61P31/00 , A61P35/00 , C07K16/28 , C12N5/0636 , C12Y304/21039 , C12Y304/24011 , C12N2501/05 , C12N2501/51 , C12N2501/515
摘要： This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signalling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signalling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signalling, a VIP degrading enzyme, and combinations thereof.
-
公开(公告)号：US11859208B2
公开(公告)日：2024-01-02
申请号：US16092068
申请日：2017-04-05
申请人： Emory University
发明人： Edmund Waller , Anna Morris , Christopher Petersen , Jian-Ming Li , Reema Panjwani , Jingxia Li
IPC分类号： C12N5/0783 , A61K45/06 , A61K38/48 , A61K35/17 , A61P35/00 , A61K38/20 , A61K39/39 , A61P31/00 , A61K35/28 , A61K38/22 , A61K38/54 , C07K16/28
CPC分类号： C12N5/0638 , A61K35/17 , A61K35/28 , A61K38/208 , A61K38/22 , A61K38/482 , A61K38/4886 , A61K38/54 , A61K39/39 , A61K45/06 , A61P31/00 , A61P35/00 , C07K16/28 , C12N5/0636 , C12Y304/21039 , C12Y304/24011 , C12N2501/05 , C12N2501/515
摘要： This disclosure relates to compositions and methods of reversing senescence in T cells by interrupting vasoactive intestinal peptide (VIP) signaling and/or inhibiting phosphatidylinositol-3-kinase (PI3 kinase) inhibitor signaling and uses in managing cancer and chronic viral infections. In certain embodiments, the disclosure contemplates methods of reversing T cell senescence by mixing T cell in vitro with an agent that prevents VIP from interacting with VIP receptors and/or a PI3 Kinase inhibitor. In certain embodiments, the disclosure contemplates the expansion of senescent T cells by mixing with a PI3 kinase inhibitor, an agent that block VIP and VIP receptor signaling, a VIP degrading enzyme, and combinations thereof.
-
公开(公告)号：US20240066101A1
公开(公告)日：2024-02-29
申请号：US18486860
申请日：2023-10-13
申请人： Emory University
发明人： Giacomo Waller , Yiwen Li , Edmund Waller
CPC分类号： A61K38/26 , A61K9/0075 , A61K9/124 , A61K47/24 , A61K47/6935
摘要： In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.
-
公开(公告)号：US11786580B2
公开(公告)日：2023-10-17
申请号：US17050348
申请日：2019-04-23
申请人： Emory University
发明人： Giacomo Waller , Yiwen Li , Edmund Waller
CPC分类号： A61K38/26 , A61K9/0075 , A61K9/124 , A61K47/24 , A61K47/6935
摘要： In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.
-
公开(公告)号：US20210187076A1
公开(公告)日：2021-06-24
申请号：US17050348
申请日：2019-04-23
申请人： Emory University
发明人： Giacomo Waller , Yiwen Li , Edmund Waller
摘要： In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.
-
公开(公告)号：US20200297767A1
公开(公告)日：2020-09-24
申请号：US16763197
申请日：2018-11-09
申请人： Emory University
IPC分类号： A61K35/17 , C07K14/575 , A61K47/69 , A61K47/62
摘要： This disclosure relates to compositions comprising an antagonist of vasoactive intestinal polypeptide signaling coupled to a nanoparticle and methods of use related thereto. In certain embodiments, the nanoparticle is a poloxamer-stabilized polypropylene sulfide nanoparticle.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.012 秒)
